山东大学耳鼻喉眼学报 ›› 2025, Vol. 39 ›› Issue (5): 114-117.doi: 10.6040/j.issn.1673-3770.0.2023.478

• 论著 • 上一篇    

眼内液检测指导精准治疗急性视网膜坏死1例并文献复习

丁术梁1,王超凡1,刘建亮2   

  1. 1. 山东第二医科大学 临床医学院, 山东 潍坊 261000;
    2.山东第二医科大学附属医院 眼科中心, 山东 潍坊 261000
  • 发布日期:2025-09-19
  • 通讯作者: 刘建亮. E-mail:ljl80929@163.com

A case of intraocular fluid detection to guide precise treatment of acute retinal necrosis and review of the literature

DING Shuliang1, WANG Chaofan1, LIU Jianliang2   

  1. 1. School of Clinical Medicine, Shandong Second Medical University, Weifang 261000, Shandong, China2. Department of Ophthalmology, Affiliated Hospital of Shandong Second Medical University, Weifang 261000, Shandong, China
  • Published:2025-09-19

摘要: 目的 探究急性视网膜坏死(acute retinal necrosis, ARN)继发难治性黄斑水肿在眼内液检测指导下使用地塞米松玻璃体内植入剂(傲迪适)的治疗效果。 方法 跟踪随访1例ARN继发难治性黄斑水肿的患者,根据眼内液检测结果精准调整治疗方案,进行前瞻性研究。 结果 本研究报道1例ARN继发难治性黄斑水肿患者在眼内液检测指导下实现精准治疗。该患者因右眼急进性视力下降4 d入院,眼内液检测到水痘-带状疱疹病毒(varicella-herpes zoster virus, VZV)。给予抗病毒治疗后视网膜炎症消失,但继发黄斑水肿,玻璃体注射雷珠单抗后黄斑水肿减轻,但易复发。在连续8周眼内液未检测到VZV后,创新性地应用傲迪适来治疗黄斑水肿,在连续3次玻璃体内注射傲迪适后黄斑水肿完全消退,且2年内未复发。 结论 本病例提示眼内液检测可指导ARN的精准诊疗,病毒完全消失后继发难治性黄斑水肿可应用傲迪适治疗,且远期疗效优于雷珠单抗。

关键词: 急性视网膜坏死, 黄斑水肿, 眼内液检测, 地塞米松玻璃体内植入剂

Abstract: Objective To evaluate the therapeutic efficacy of dexamethasone intravitreal implant(Ozurdex)in refractory macular edema secondary to acute retinal necrosis(ARN)guided by intraocular fluid detection. Methods One patient with refractory macular edema secondary to ARN was followed up, and the treatment regimen was precisely adjusted according to the intraocular fluid detection results in a prospective study. Results This study reports on a patient with refractory macular edema secondary to ARN who received precise treatment guided by the detection of intraocular fluid. The patient was admitted to hospital with acute progressive visual loss in the right eye for 4 d. Varicella herpes zoster virus(VZV)was detected in the intraocular fluid. The retinal inflammation resolved after administration of antiviral therapy, but there was secondary macular edema, which resolved after vitreous injection of Ranibizumab but was prone to recurrence. After 8 consecutive weeks of undetectable VZV in the intraocular fluid, Ozurdex was innovatively used to treat macular edema, which resolved completely after 3 consecutive intravitreal injections of Ozurdex and did not recur for 2 years. Conclusion This case suggests that detection of intraocular fluid can guide accurate diagnosis and treatment of ARN, and that refractory macular edema following viral clearance can be treated with Ozurdex, which has better long-term efficacy than Ranibizumab.

Key words: Acute retinal necrosis, Macular edema, Intraocular fluid detection, Dexamethasone intravitreal implant

中图分类号: 

  • R774.1
[1] Schoenberger SD, Kim SJ, Thorne JE, et al. Diagnosis and treatment of acute retinal necrosis: a report by the American academy of ophthalmology[J]. Ophthalmology, 2017, 124(3): 382-392. doi:10.1016/j.ophtha.2016.11.007
[2] Shiezadeh E, Hosseini SM, Bakhtiari E, et al. Clinical characteristics and management outcomes of acute retinal necrosis[J]. Sci Rep, 2023, 13(1): 16927. doi:10.1038/s41598-023-44310-4
[3] Takase H, Okada AA, Goto H, et al. Development and validation of new diagnostic criteria for acute retinal necrosis[J]. Jpn J Ophthalmol, 2015, 59(1): 14-20. doi:10.1007/s10384-014-0362-0
[4] 刘瑄, 陶勇. 用好眼内液检测[J]. 中华眼科医学杂志(电子版), 2018, 8(5): 193-201. doi:10.3877/cma.j.issn.2095-2007.2018.05.001 LIU Xuan, TAO Yong. Use the examination of intraocular fluid well[J]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2018, 8(5): 193-201. doi:10.3877/cma.j.issn.2095-2007.2018.05.001
[5] Thorne JE,Sugar EA,Holbrook JT,et al. Periocular triamcinolone vs. intravitreal triamcinolone vs. intravitreal dexamethasone implant for the treatment of uveitic macular edema: the PeriOcular vs. INTravitreal corticosteroids for uveitic macular edema(POINT)trial[J]. Ophthalmology, 2019, 126(2): 283-295. doi:10.1016/j.ophtha.2018.08.021
[6] Calvo CM, Khan MA, Mehta S, et al. Correlation of clinical outcomes with quantitative polymerase chain reaction DNA copy number in patients with acute retinal necrosis[J]. Ocul Immunol Inflamm, 2017, 25(2): 246-252. doi:10.3109/09273948.2015.1115081
[7] Dokey AT, Haug SJ, McDonald HR, et al. Acute retinal necrosis secondary to multidrug-resistant herpes simplex virus 2 in an immunocompetent adolescent[J]. Retin Cases Brief Rep, 2014, 8(4): 260-264. doi:10.1097/ICB.0000000000000096
[8] Bograd A, Villiger PM, Munk MR, et al. Tocilizumab and aflibercept as a treatment option for refractory macular edema after acute retinal necrosis[J]. Ocul Immunol Inflamm, 2023, 31(1): 242-245. doi:10.1080/09273948.2021.2024580
[9] Majumder PD, Biswas J, Ambreen A, et al. Intravitreal dexamethasone implant for the treatment of cystoid macular oedema associated with acute retinal necrosis[J]. J Ophthalmic Inflamm Infect, 2016, 6(1): 49. doi:10.1186/s12348-016-0116-x
[10] Wu P, Xing X, Huan Y, et al. Intravitreal dexamethasone implants for macular edema secondary to acute retinal necrosis[J]. Ocul Immunol Inflamm, 2024, 9: 1-7. doi: 10.1080/09273948.2024.2413692
[11] Copete S, García-García JG, Júdez E. Dexamethasone intravitreal implant in the treatment of macular edema secondary to necrotizing retinitis[J]. Eur J Ophthalmol, 2024, 34(6): 19-23. doi: 10.1177/11206721241275729
[1] 沈嘉琪,李潇飒,毕燕龙,张敬法. 人工智能在DME筛查、诊断和预后中的应用[J]. 山东大学耳鼻喉眼学报, 2024, 38(5): 153-159.
[2] 鲍莹,刘志高,姜鹏飞,崔文轩,郑晓霞,杨梦瑶,司明威,王玉,王红. 康柏西普治疗糖尿病合并CRVO-ME高反射点的临床观察[J]. 山东大学耳鼻喉眼学报, 2024, 38(3): 55-60.
[3] 常威威,焦万珍,崔艳艳,赵杰,刘兆强,赵博军. 糖尿病性黄斑缺血的研究进展[J]. 山东大学耳鼻喉眼学报, 2024, 38(3): 130-136.
[4] 周静琳,李金香,曾琦. 577 nm阈值下微脉冲激光联合抗VEGF药物治疗难治性糖尿病性黄斑水肿的疗效观察[J]. 山东大学耳鼻喉眼学报, 2024, 38(2): 18-25.
[5] 何静,雷春燕,张美霞. 糖化血红蛋白变异指数与糖尿病视网膜病变严重程度的相关性研究[J]. 山东大学耳鼻喉眼学报, 2024, 38(2): 34-40.
[6] 顾冉冉,李凤娇,焦万珍,崔艳艳,赵博军. 卵磷脂络和碘胶囊辅助治疗视网膜静脉阻塞的临床疗效研究[J]. 山东大学耳鼻喉眼学报, 2022, 36(5): 46-50.
[7] 韩克阳,于贝贝,赵博军. 短期视网膜静脉阻塞抗VEGF治疗后黄斑区形态结构分析[J]. 山东大学耳鼻喉眼学报, 2019, 33(5): 129-131.
[8] 刘建波,张环. 超声乳化联合玻璃体腔药物注射治疗白内障合并糖尿病性黄斑水肿[J]. 山东大学耳鼻喉眼学报, 2019, 33(2): 99-104.
[9] 靳琳,潘庆敏,胡磊. 玻璃体腔注射雷珠单抗治疗CSME及NCSME的临床观察[J]. 山东大学耳鼻喉眼学报, 2017, 31(2): 96-98.
[10] 严槟,尹小芳,叶祖科,卢彦,洪剑威. 玻璃体腔注射雷珠单抗联合GLP治疗BRVO-ME的临床观察[J]. 山东大学耳鼻喉眼学报, 2017, 31(1): 110-113.
[11] 韩克阳,王淑雅,焦芮,于贝贝, 赵博军. 视网膜静脉阻塞的发病机制及黄斑水肿的抗-VEGF治疗[J]. 山东大学耳鼻喉眼学报, 2017, 31(1): 123-126.
[12] 严晓腾,冯军,康欣乐. 玻璃体腔注射康柏西普治疗视网膜静脉阻塞继发黄斑水肿的临床观察[J]. 山东大学耳鼻喉眼学报, 2016, 30(4): 105-108.
[13] 邢凯,亢泽峰. 玻璃体腔内注射康柏西普治疗视网膜分支静脉阻塞继发黄斑水肿的疗效分析[J]. 山东大学耳鼻喉眼学报, 2016, 30(1): 80-82.
[14] 严晓腾, 冯军, 康欣乐. 曲安奈德玻璃体腔注射联合格栅样光凝治疗囊样黄斑水肿[J]. 山东大学耳鼻喉眼学报, 2015, 29(1): 60-63.
[15] 孙洪义, 张晗. 2型糖尿病患者超声乳化白内障摘除并人工晶体植入手术后黄斑区光学相干断层扫描改变[J]. 山东大学耳鼻喉眼学报, 2014, 28(6): 72-76.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!